PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY INDICATION • Segmentation by indication • Comparison by indication • MD drugs • DED drugs • Others • Market opportunity by indication PART 08: MARKET SEGMENTATION BY DRUG CLASS • Segmentation by drug class • Anti-VEGF agents • Corticosteroids • Others PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Retinal drugs market in Americas • Retinal drugs market in EMEA • Retinal drugs market in APAC • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Development of innovative therapies • Rise in demand for sustained-release ocular formulations PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS0 • Vendors covered • Vendor classification • Market positioning of vendors • ALLERGAN • Bayer • F. Hoffmann-La Roche • Novartis • Regeneron Pharmaceuticals • Valeant Pharmaceuticals PART 16: APPENDIX • List of abbreviations • Exhibit 01: Parent market • Exhibit 02: Global ophthalmic drugs market segmentation • Exhibit 03: Market characteristics • Exhibit 04: Market segments • Exhibit 05: Market definition - Inclusions and exclusions checklist • Exhibit 06: Market size 2017 • Exhibit 07: Validation techniques employed for market sizing 2017 • Exhibit 08: Global retinal drugs market – Market size and forecast 2017-2022 ($ mn) • Exhibit 09: Global retinal drugs market – Year-over-year growth 2018-2022 (%) • Exhibit 10: Five forces analysis 2017 • Exhibit 11: Five forces analysis 2022 • Exhibit 12: Bargaining power of buyers • Exhibit 13: Bargaining power of suppliers • Exhibit 14: Threat of new entrants • Exhibit 15: Threat of substitutes • Exhibit 16: Threat of rivalry • Exhibit 17: Market condition - Five forces 2017 • Exhibit 18: Global retinal drugs market – Market share by indication 2017-2022 (%) • Exhibit 19: Comparison by indication • Exhibit 20: Global MD drugs market – Market size and forecast 2017-2022 ($ mn) • Exhibit 21: Global MD drugs market – Year-over-year growth 2018-2022 (%) • Exhibit 22: Global DED drugs market – Market size and forecast 2017-2022 ($ mn) • Exhibit 23: Global DED drugs market – Year-over-year growth 2018-2022 (%) • Exhibit 24: Global other retinal diseases drugs market – Market size and forecast 2017-2022 ($ mn) • Exhibit 25: Global other retinal diseases drugs market – Year-over-year growth 2018-2022 (%) • Exhibit 26: Market opportunity by indication • Exhibit 27: Global retinal drugs market share by drug class 2017 (%) • Exhibit 28: Major anti-VEGF agents approved in the market • Exhibit 29: Major corticosteroids approved in the market • Exhibit 30: Customer landscape • Exhibit 31: Global retinal drugs market – Market share by geography 2017-2022 (%) • Exhibit 32: Regional comparison • Exhibit 33: Retinal drugs market in Americas – Market size and forecast 2017-2022 ($ mn) • Exhibit 34: Retinal drugs market in Americas – Year-over-year growth 2018-2022 (%) • Exhibit 35: Top 3 countries in Americas • Exhibit 36: Retinal drugs market in EMEA – Market size and forecast 2017-2022 ($ mn) • Exhibit 37: Retinal drugs market in EMEA – Year-over-year growth 2018-2022 (%) • Exhibit 38: Top 3 countries in EMEA • Exhibit 39: Retinal drugs market in APAC – Market size and forecast 2017-2022 ($ mn) • Exhibit 40: Retinal drugs market in APAC – Year-over-year growth 2018-2022 (%) • Exhibit 41: Top 3 countries in APAC • Exhibit 42: Market opportunity • Exhibit 43: Vendor landscape • Exhibit 44: Landscape disruption • Exhibit 45: Vendors covered • Exhibit 46: Vendor classification • Exhibit 47: Market positioning of vendors • Exhibit 48: ALLERGAN – Overview • Exhibit 49: ALLERGAN – Business segments • Exhibit 50: ALLERGAN – Organizational developments • Exhibit 51: ALLERGAN – Geographic focus • Exhibit 52: ALLERGAN – Segment focus • Exhibit 53: ALLERGAN – Key offering • Exhibit 54: ALLERGAN – Key customers • Exhibit 55: Bayer – Overview • Exhibit 56: Bayer – Business segments • Exhibit 57: Bayer – Organizational developments • Exhibit 58: Bayer – Geographic focus • Exhibit 59: Bayer – Segment focus • Exhibit 60: Bayer – Key offerings • Exhibit 61: Bayer – Key customers • Exhibit 62: F. Hoffmann-La Roche – Overview • Exhibit 63: F. Hoffmann-La Roche – Business segments • Exhibit 64: F. Hoffmann-La Roche – Organizational developments • Exhibit 65: F. Hoffmann-La Roche – Geographic focus • Exhibit 66: F. Hoffmann-La Roche – Segment focus • Exhibit 67: F. Hoffmann-La Roche – Key offerings • Exhibit 68: F. Hoffmann-La Roche – Key customers • Exhibit 69: Novartis – Overview • Exhibit 70: Novartis – Business segments • Exhibit 71: Novartis – Organizational developments • Exhibit 72: Novartis – Geographic focus • Exhibit 73: Novartis – Segment focus • Exhibit 74: Novartis – Key offerings • Exhibit 75: Novartis – Key customers • Exhibit 76: Regeneron Pharmaceuticals – Overview • Exhibit 77: Regeneron Pharmaceuticals – Business segments • Exhibit 78: Regeneron Pharmaceuticals – Organizational developments • Exhibit 79: Regeneron Pharmaceuticals – Geographic focus • Exhibit 80: Regeneron Pharmaceuticals – Segment focus • Exhibit 81: Regeneron Pharmaceuticals – Key offerings • Exhibit 82: Regeneron Pharmaceuticals – Key customers • Exhibit 83: Valeant Pharmaceuticals – Overview • Exhibit 84: Valeant Pharmaceuticals – Business segments • Exhibit 85: Valeant Pharmaceuticals – Organizational developments • Exhibit 86: Valeant Pharmaceuticals – Geographic focus • Exhibit 87: Valeant Pharmaceuticals – Segment focus • Exhibit 88: Valeant Pharmaceuticals – Key offerings • Exhibit 89: Valeant Pharmaceuticals – Key customers

ALLERGAN, Bayer, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, and Valeant Pharmaceuticals.